Jay S. Duker, MD

CHICAGO — In this Healio Video Perspective from the AAO meeting, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, shares an update on Duravyu for wet age-related macular degeneration.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Jay S. Duker, MD, of EyePoint Pharmaceuticals discusses lead product Duravyu.

WAILEA, Hawaii — In this Healio video perspective from Hawaiian Eye/Retina 2024, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses the phase 2 DAVIO 2 results for EYP-1901 for the treatment of wet AMD.

A 58-year-old white woman was referred to the retina service at the New England Eye Center for a new right eye choroidal mass.

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2023, Jay S. Duker, MD, discusses EyePoint Pharmaceuticals’ EYP-1901, a tyrosine kinase inhibitor for patients with wet AMD.

In this Healio Video Perspective, Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, discusses EYP-1901 for the treatment of wet age-related macular degeneration.

WAILEA, Hawaii — In this video from Hawaiian Eye, Jay S. Duker, MD, chief strategic scientific officer at EyePoint, discusses the development of a long-acting, sustained release, bio-erodible implant for the treatment of retinal disease.

A 61-year-old woman was referred to the New England Eye Center’s comprehensive ophthalmology service with decreased vision in the left eye.

An 8-year-old healthy girl presented to the New England Eye Center retina service for evaluation of a retinal lesion in the right eye.

An 80-year-old retired firefighter with a history of wet age-related macular degeneration since 1990 presented to the retinal specialist for new intermittent severe left throbbing eye pain over the past month. The pain woke him up from sleep and was so severe at times that he wanted to “pluck [his] eyeball out of the socket.” He denied flashes or floaters. He reported his vision was slightly dimmer at times in this eye. He was pseudophakic in both eyes, and he had been followed by his retinal specialist regularly for the past 28 years. He had a history of subretinal surgery with choroidal neovascularization removal in the left eye in 1995. Since then, his left eye had undergone no other treatment except cataract surgery. His right eye had developed wet AMD 10 years before the current presentation and was receiving regular anti-VEGF injections.